Literature DB >> 20635852

Omega-3 fatty acid supplementation and reduction of traumatic axonal injury in a rodent head injury model.

James D Mills1, Julian E Bailes, Cara L Sedney, Heather Hutchins, Barry Sears.   

Abstract

OBJECT: Traumatic brain injury remains the most common cause of death in persons under 45 years of age in the Western world. Recent evidence from animal studies suggests that supplementation with omega-3 fatty acid (O3FA) (particularly eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) improves functional outcomes following focal neural injury. The purpose of this study is to determine the benefits of O3FA supplementation following diffuse axonal injury in rats.
METHODS: Forty adult male Sprague-Dawley rats were used. Three groups of 10 rats were subjected to an impact acceleration injury and the remaining group underwent a sham-injury procedure (surgery, but no impact injury). Two of the groups subjected to the injury were supplemented with 10 or 40 mg/kg/day of O3FA; the third injured group served as an unsupplemented control group. The sham-injured rats likewise received no O3FA supplementation. Serum fatty acid levels were determined from the isolated plasma phospholipids prior to the injury and at the end of the 30 days of supplementation. After the animals had been killed, immunohistochemical analysis of brainstem white matter tracts was performed to assess the presence of β-amyloid precursor protein (APP), a marker of axonal injury. Immunohistochemical analyses of axonal injury mechanisms-including analysis for caspase-3, a marker of apoptosis; RMO-14, a marker of neurofilament compaction; and cytochrome c, a marker of mitochondrial injury-were performed.
RESULTS: Dietary supplementation with a fish oil concentrate rich in EPA and DHA for 30 days resulted in significant increases in O3FA serum levels: 11.6% ± 4.9% over initial levels in the 10 mg/kg/day group and 30.7% ± 3.6% in the 40 mg/kg/day group. Immunohistochemical analysis revealed significantly (p < 0.05) decreased numbers of APP-positive axons in animals receiving O3FA supplementation: 7.7 ± 14.4 axons per mm(2) in the 10 mg/kg/day group and 6.2 ± 11.4 axons per mm(2) in the 40 mg/kg/day group, versus 182.2 ± 44.6 axons per mm(2) in unsupplemented animals. Sham-injured animals had 4.1 ± 1.3 APP-positive axons per mm(2). Similarly, immunohistochemical analysis of caspase-3 expression demonstrated significant (p < 0.05) reduction in animals receiving O3FA supplementation, 18.5 ± 28.3 axons per mm(2) in the 10 mg/kg/day group and 13.8 ± 18.9 axons per mm(2) in the 40 mg/kg/day group, versus 129.3 ± 49.1 axons per mm(2) in unsupplemented animals.
CONCLUSIONS: Dietary supplementation with a fish oil concentrate rich in the O3FAs EPA and DHA increases serum levels of these same fatty acids in a dose-response effect. Omega-3 fatty acid supplementation significantly reduces the number of APP-positive axons at 30 days postinjury to levels similar to those in uninjured animals. Omega-3 fatty acids are safe, affordable, and readily available worldwide to potentially reduce the burden of traumatic brain injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20635852     DOI: 10.3171/2010.5.JNS08914

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  36 in total

1.  Oral fish oil restores striatal dopamine release after traumatic brain injury.

Authors:  Samuel S Shin; C Edward Dixon
Journal:  Neurosci Lett       Date:  2011-04-14       Impact factor: 3.046

Review 2.  The combined effects of exercise and foods in preventing neurological and cognitive disorders.

Authors:  Fernando Gomez-Pinilla
Journal:  Prev Med       Date:  2011-01-31       Impact factor: 4.018

Review 3.  Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders.

Authors:  Gregory E Bigford; Gianluca Del Rossi
Journal:  Adv Nutr       Date:  2014-07-14       Impact factor: 8.701

4.  Elucidating the severity of preclinical traumatic brain injury models: a role for functional assessment?

Authors:  Ryan C Turner; Reyna L VanGilder; Zachary J Naser; Brandon P Lucke-Wold; Julian E Bailes; Rae R Matsumoto; Jason D Huber; Charles L Rosen
Journal:  Neurosurgery       Date:  2014-04       Impact factor: 4.654

5.  Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons.

Authors:  Hongtao Wu; Asim Mahmood; Changsheng Qu; Ye Xiong; Michael Chopp
Journal:  Brain Res       Date:  2012-09-28       Impact factor: 3.252

6.  A Pilot Study Assessing the Impact of rs174537 on Circulating Polyunsaturated Fatty Acids and the Inflammatory Response in Patients with Traumatic Brain Injury.

Authors:  Charlotte Mae K Waits; Aaron Bower; Kelli N Simms; Bradford C Feldman; Nathan Kim; Susan Sergeant; Floyd H Chilton; Pamela J VandeVord; Carl D Langefeld; Elaheh Rahbar
Journal:  J Neurotrauma       Date:  2020-05-07       Impact factor: 5.269

Review 7.  Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil?

Authors:  Martin D Rosenthal; Jayshil Patel; Kyle Staton; Robert G Martindale; Frederick A Moore; Gilbert R Upchurch
Journal:  Curr Gastroenterol Rep       Date:  2018-08-04

8.  Therapy development for diffuse axonal injury.

Authors:  Douglas H Smith; Ramona Hicks; John T Povlishock
Journal:  J Neurotrauma       Date:  2013-02-14       Impact factor: 5.269

Review 9.  The More, the Better: High-Dose Omega-3 Fatty Acids Improve Behavioural and Molecular Outcomes in Preclinical Models in Mild Brain Injury.

Authors:  Craig S Patch; Elisa L Hill-Yardin; Michael Lewis; Lisa Ryan; Ed Daly; Alan J Pearce
Journal:  Curr Neurol Neurosci Rep       Date:  2021-07-06       Impact factor: 5.081

Review 10.  Inflammation in Traumatic Brain Injury.

Authors:  Teodor T Postolache; Abhishek Wadhawan; Adem Can; Christopher A Lowry; Margaret Woodbury; Hina Makkar; Andrew J Hoisington; Alison J Scott; Eileen Potocki; Michael E Benros; John W Stiller
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.